From: Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection
Disease group
Mechanism for severe RSV infection
Reduced ventilation competencea
Difficulty in expectorationb
Pulmonary hypoplasia
○
Airway stenosis
Congenital esophageal atresia
Δ
Inherited metabolic disease
Neuromuscular disease